AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 44.3 |
Market Cap | 5.33B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -5.38 |
PE Ratio (ttm) | -8.39 |
Forward PE | n/a |
Analyst | Buy |
Ask | 48.5 |
Volume | 1,045,518 |
Avg. Volume (20D) | 1,176,872 |
Open | 47.01 |
Previous Close | 46.71 |
Day's Range | 44.78 - 47.30 |
52-Week Range | 44.49 - 86.63 |
Beta | undefined |
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...
Analyst Forecast
According to 15 analyst ratings, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $80, which is an increase of 77.13% from the latest price.
Next Earnings Release
Analysts project revenue of $10.42M, reflecting a 523.21% YoY growth and earnings per share of -1.26, making a -8.70% decrease YoY.